TABLE 5.
Reference | Risk of Bias | Applicability Concerns | |||||
---|---|---|---|---|---|---|---|
Patient Selection | Index Test | Reference Standard | Flow and Timing | Patient Selection | Index Test | Reference Standard | |
Dabigatran Studies | |||||||
10 | L | U | U | L | L | H | H |
11 | NA | U | U | L | H | H | H |
12 | NA | U | U | L | H | H | H |
13 | NA | U | L | L | H | L | H |
14 | NA | U | L | L | H | H | H |
15 | NA | L | L | L | H | L | H |
16 | NA | U | L | L | H | H | H |
17 | NA | U | L | L | H | L | H |
18 | NA | U | L | L | H | H | H |
19 | NA | U | L | L | H | H | H |
20 | NA | U | L | L | H | H | H |
21 | NA | U | L | L | H | L | H |
22 | U | U | U | L | L | H | H |
23 | U | U | U | L | L | H | H |
24 | U | U | U | L | L | H | H |
25 | NA | U | L | L | H | L | H |
26 | NA | U | L | L | H | L | H |
Rivaroxaban Studies | |||||||
26 | NA | U | U | L | H | L | H |
36 | NA | U | U | L | L | L | H |
37 | NA | U | L | L | H | H | H |
38 | U | U | U | L | L | L | H |
39 | NA | U | L | L | H | L | H |
40 | NA | U | L | L | H | L | H |
41 | NA | U | L | L | H | L | H |
42 | NA | L | L | L | H | L | H |
43 | U | U | U | L | L | L | H |
44 | NA | U | L | L | H | L | H |
45 | NA | L | L | L | H | L | H |
46 | NA | L | L | L | H | L | H |
47 | NA | U | L | L | H | L | H |
48 | U | U | U | L | L | L | H |
49 | U | U | U | L | L | L | H |
Apixaban Studies | |||||||
36 | L | U | U | L | L | L | H |
53 | L | U | U | L | H | L | H |
54 | NA | U | U | L | H | L | H |
55 | NA | L | L | L | H | L | H |
H = high; L = low; U = unclear; other abbreviations as in Table 2.